Open Payments

BOSTON MEDICAL CENTER

Type
Teaching hospital
Where
BOSTON, MA
Medicare CCN
220031
Received
$5,097,680 in 510 records, 2023 ($804,688 general, $4,292,992 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment83$804,688
2023Research payment427$4,292,992

By company

CompanyRecordsAmountYears
PFIZER INC.87$1,521,3972023
Merck Sharp & Dohme LLC11$581,9552023
Gilead Sciences, Inc.1$291,6772023
Janssen Research & Development, LLC77$287,4542023
Eli Lilly and Company3$280,0782023
E.R. Squibb & Sons, L.L.C.3$219,6372023
VERTEX PHARMACEUTICALS INCORPORATED3$217,4272023
Alexion Pharmaceuticals, Inc.3$201,5582023
COLOPLAST CORP1$125,0002023
G1 Therapeutics, Inc.10$124,6722023
Acutus Medical, Inc.1$95,0002023
Biogen, Inc.1$84,1502023
Takeda Pharmaceuticals U.S.A., Inc.19$83,4702023
KARL STORZ Endoscopy-America40$82,8372023
Intercept Pharma Europe Ltd.10$80,1372023
Acera Surgical, Inc.4$78,1732023
C. R. Bard, Inc. & Subsidiaries2$72,2112023
Indivior Inc.13$64,9962023
Mannkind Corporation3$62,6872023
Agios Pharmaceuticals, Inc.16$55,4542023
Tandem Diabetes Care, Inc.1$48,7072023
GLOBAL BLOOD THERAPEUTICS, INC.3$43,4472023
INSTYLLA, INC.2$33,3422023
Novo Nordisk AS91$32,5462023
Medline Industries LP8$31,0682023
Genentech, Inc.2$30,8952023
ABBVIE INC.11$30,2052023
Route 92 Medical, Inc.1$28,7702023
GlaxoSmithKline, LLC.6$28,6672023
CSL Behring4$19,3752023
RedDress LTD1$18,1992023
Intercept Pharmaceuticals, Inc.2$17,9362023
Akcea Therapeutics, Inc.1$17,4632023
Boston Scientific Corporation14$16,2262023
KLS-Martin L.P.4$15,0002023
Immedica Pharma US, Inc.9$14,9532023
Acrotech Biopharma Inc.3$13,5712023
Bard Peripheral Vascular, Inc.1$10,0002023
Organon Llc4$7,5842023
AstraZeneca Pharmaceuticals LP1$5,7252023
Philips North America LLC2$4,2002023
BIOTISSUE HOLDINGS INC.8$4,0502023
Celgene Corporation1$3,7862023
Stryker Corporation1$3,0262023
Evofem Biosciences, Inc.1$2,0202023
Laminate Medical Technologies inc.1$1,9112023
Merck Healthcare KGaA1$1,3002023
Abbott Laboratories7$1,2852023
GUERBET LLC4$5642023
Fisher Scientific Company L.L.C.1$5412023

By nature of payment

NatureRecordsAmount
Research payment427$4,292,992
Grant9$555,827
Education41$177,837
Compensation for services other than consulting, including serving as faculty or as a speaker at a v13$64,996
Debt forgiveness3$3,602
Charitable Contribution15$1,384
Consulting Fee1$541
Space rental or facility fees (teaching hospital only)1$500

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-31Gilead Sciences, Inc.$291,677GrantCash or cash equivalent2023
2023-12-31Merck Sharp & Dohme LLC$28,678Research paymentIn-kind items and servicesGARDASIL 9 Biological, VACCINEAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen over a Fo2023
2023-12-31Merck Sharp & Dohme LLC$28,436Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792023
2023-12-31RedDress LTD$18,199Research paymentCash or cash equivalentA Multi-Center, Prospective, Randomized, Controlled, Trial, Comparing the Safety and Efficacy of ActiGraft Pro to Standa2023
2023-12-31Merck Sharp & Dohme LLC$14,843Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792023
2023-12-31Merck Sharp & Dohme LLC$10,697Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2023
2023-12-31KARL STORZ Endoscopy-America$4,286EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31Stryker Corporation$3,026Debt forgivenessCash or cash equivalent2023
2023-12-31Philips North America LLC$3,000Research paymentIn-kind items and services(6260) Ingenia 3 0T R5 Device, Medical DeviceTRUST and ASE for Global Blood Therapeutics Voxelotor Trial2023
2023-12-31KARL STORZ Endoscopy-America$2,591EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$2,039EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$2,039EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31Philips North America LLC$1,200Research paymentIn-kind items and services(6260) Ingenia 3 0T R5 Device, Medical DeviceTRUST and ASE for Global Blood Therapeutics Voxelotor Trial2023
2023-12-31KARL STORZ Endoscopy-America$916EducationIn-kind items and services2023
2023-12-31KARL STORZ Endoscopy-America$880EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$838EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$730EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$730EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$730EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$730EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31ABBVIE INC.$500Research paymentIn-kind items and servicesSafety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco2023
2023-12-31ABBVIE INC.$500Research paymentIn-kind items and servicesSafety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco2023
2023-12-31Merck Sharp & Dohme LLC$435Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2023
2023-12-31KARL STORZ Endoscopy-America$423EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$283EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$213EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$186EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$154EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$136EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$120EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-31KARL STORZ Endoscopy-America$60EducationIn-kind items and services2023
2023-12-31KARL STORZ Endoscopy-America$55EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-30PFIZER INC.$6,276Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-12-26Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-12-22PFIZER INC.$6,605Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2023
2023-12-22Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2023
2023-12-21Intercept Pharma Europe Ltd.$2,197Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-12-21Intercept Pharma Europe Ltd.$360Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-12-18Immedica Pharma US, Inc.$9,179Research paymentCash or cash equivalentA Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St2023
2023-12-18Janssen Research & Development, LLC$238Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2023
2023-12-11KARL STORZ Endoscopy-America$25,922EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-11KARL STORZ Endoscopy-America$2,165EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-07Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-12-05KARL STORZ Endoscopy-America$1,509EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-04KARL STORZ Endoscopy-America$1,372EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-04KARL STORZ Endoscopy-America$476EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-12-04PFIZER INC.$403Research paymentIn-kind items and servicesA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2023
2023-12-02PFIZER INC.$27,202Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2023
2023-12-01Organon Llc$989Research paymentCash or cash equivalentEfficacy and Safety of Nexplanon 36 to 60 Months Post Insertion2023
2023-11-30Mannkind Corporation$8,742Research paymentCash or cash equivalentAFREZZA Drug, DIABETES MEDICINEINHALE-32023
2023-11-30KARL STORZ Endoscopy-America$3,495EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-30KARL STORZ Endoscopy-America$3,280EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-30KARL STORZ Endoscopy-America$3,126EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-30KARL STORZ Endoscopy-America$2,876EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-30KARL STORZ Endoscopy-America$2,763EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-30KARL STORZ Endoscopy-America$2,665EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-30KARL STORZ Endoscopy-America$2,098EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-30KARL STORZ Endoscopy-America$782EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-30KARL STORZ Endoscopy-America$270EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-30PFIZER INC.$118Research paymentIn-kind items and servicesPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2023
2023-11-30KARL STORZ Endoscopy-America$23EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-28Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2023
2023-11-28KARL STORZ Endoscopy-America$1,980EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-28KARL STORZ Endoscopy-America$1,938EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-28KARL STORZ Endoscopy-America$1,769EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-28GlaxoSmithKline, LLC.$1,300Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2023
2023-11-28KARL STORZ Endoscopy-America$180EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-27Eli Lilly and Company$222,675Research paymentCash or cash equivalent2023
2023-11-27Novo Nordisk AS$2,991Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522023
2023-11-27Novo Nordisk AS$375Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522023
2023-11-24Janssen Research & Development, LLC$44,667Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2023
2023-11-23PFIZER INC.$715Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2023
2023-11-22Intercept Pharma Europe Ltd.$812Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-11-21KARL STORZ Endoscopy-America$5,991EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2023
2023-11-17Janssen Research & Development, LLC$6,350Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2023
2023-11-17Takeda Pharmaceuticals U.S.A., Inc.$1,300Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF TAK-079 2023
2023-11-15E.R. Squibb & Sons, L.L.C.$169,545Research paymentCash or cash equivalentCharacterization of combined DGK2023
2023-11-15PFIZER INC.$14,560Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-11-15AstraZeneca Pharmaceuticals LP$5,725Research paymentCash or cash equivalentA Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Part2023
2023-11-15PFIZER INC.$1,105Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-11-14Merck Healthcare KGaA$1,300Research paymentCash or cash equivalentTEPMETKO Drug, OncologyA Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no2023
2023-11-14ABBVIE INC.$1,137Research paymentCash or cash equivalentSafety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco2023
2023-11-11E.R. Squibb & Sons, L.L.C.$134Research paymentCash or cash equivalentCAMZYOS Drug, VirologyA Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obst2023
2023-11-10Mannkind Corporation$33,599Research paymentCash or cash equivalentAFREZZA Drug, DIABETES MEDICINEINHALE-32023
2023-11-09PFIZER INC.$1,925Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-11-08Merck Sharp & Dohme LLC$264,999Research paymentCash or cash equivalentGARDASIL 9 Biological, VACCINEAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen over a Fo2023
2023-11-07Eli Lilly and Company$57,385Research paymentCash or cash equivalentA STUDY OF LY3540378 IN PARTICIPANTS WITH WORSENING CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)2023
2023-11-06Janssen Research & Development, LLC$238Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2023
2023-11-02Intercept Pharma Europe Ltd.$5,411Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-11-02Intercept Pharma Europe Ltd.$897Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-11-02Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-11-01INSTYLLA, INC.$8,720Research paymentCash or cash equivalentINSTYLLA MICROCATHETER Device, Liquid Embolics for Interventional RadiologyRandomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of2023
2023-10-30PFIZER INC.$137,066Research paymentCash or cash equivalentULTRASTRUCTURAL ANALYSIS OF PODOCYTE FOOT PROCESS WIDTH AND OTHER HISTOLOGICAL ANALYSES OF KIDNEY DISEASE SAMPLES AND BI2023
2023-10-30Acera Surgical, Inc.$56,368Research paymentCash or cash equivalentRestrata Wound Matrix Device, Wound CareAssessment of Wound Closure Comparing Synthetic Hybrid- Scale Fiber Matrix with Lyophilized Acellular Fish Skin in Treat2023
2023-10-30Acera Surgical, Inc.$2,430Research paymentCash or cash equivalentRestrata Wound Matrix Device, Wound CareAssessment of Wound Closure Comparing Synthetic Hybrid- Scale Fiber Matrix with Lyophilized Acellular Fish Skin in Treat2023
2023-10-27Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2023
2023-10-27Indivior Inc.$4,998Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2023
2023-10-26PFIZER INC.$345Research paymentIn-kind items and servicesCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2023
2023-10-23Novo Nordisk AS$2,012Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522023
2023-10-19Intercept Pharma Europe Ltd.$35,746Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-10-19Intercept Pharma Europe Ltd.$2,730Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-10-19PFIZER INC.$1,300Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-10-18KLS-Martin L.P.$3,750GrantCash or cash equivalent2023
2023-10-18PFIZER INC.$1,434Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2023
2023-10-17COLOPLAST CORP$125,000GrantCash or cash equivalentTitan Device, Men's Health2023
2023-10-17GlaxoSmithKline, LLC.$13,000Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2023
2023-10-17GlaxoSmithKline, LLC.$5,392Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2023
2023-10-17GlaxoSmithKline, LLC.$4,225Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2023
2023-10-17GlaxoSmithKline, LLC.$3,250Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2023
2023-10-17GlaxoSmithKline, LLC.$1,500Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2023
2023-10-16Janssen Research & Development, LLC$26,067Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2023
2023-10-10Abbott Laboratories$46Research paymentIn-kind items and servicesFreeStyle Libre 2 Device, Diabetes CareEvaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People with T2 Diabetes2023
2023-10-05Novo Nordisk AS$69Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-10-05Novo Nordisk AS$60Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-10-05Novo Nordisk AS$32Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-10-05Novo Nordisk AS$15Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-10-05Novo Nordisk AS$5Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-10-04Merck Sharp & Dohme LLC$111,919Research paymentCash or cash equivalentISENTRESS Drug, INFECTIOUS DISEASEIntensified antiretroviral therapy with raltegravir in acute HIV infection to limit establishment of the viral reservoir2023
2023-10-02Janssen Research & Development, LLC$714Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2023
2023-09-26Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-09-26Novo Nordisk AS$10Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-09-23PFIZER INC.$717Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2023
2023-09-22Novo Nordisk AS$426Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522023
2023-09-22Novo Nordisk AS$375Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522023
2023-09-15PFIZER INC.$1,034Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2023
2023-09-13G1 Therapeutics, Inc.$49,211Research paymentCash or cash equivalentCOSELA Drug, OncologyG1T28-2072023
2023-09-11PFIZER INC.$23,642Research paymentCash or cash equivalentMEASURING PODOCYTE URINARY BIOMARKERS ACROSS RENAL DISORDERS2023
2023-09-11Agios Pharmaceuticals, Inc.$1,625Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-09-11Janssen Research & Development, LLC$476Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2023
2023-09-11Agios Pharmaceuticals, Inc.$65Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-09-07PFIZER INC.$30,362Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-09-02PFIZER INC.$8,484Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2023
2023-09-01Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-09-01Eli Lilly and Company$18Research paymentIn-kind items and servicesA STUDY OF LY3540378 IN PARTICIPANTS WITH WORSENING CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)2023
2023-09-01Novo Nordisk AS$3Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522023
2023-08-31Route 92 Medical, Inc.$28,770Research paymentCash or cash equivalentHIPOINT 088 Device, NEURO ASPIRATIONSUMMIT MAX2023
2023-08-31QIAGEN, LLC$442Debt forgivenessCash or cash equivalent2023
2023-08-31Abbott Laboratories$90Research paymentIn-kind items and servicesFreeStyle Libre 2 Device, Diabetes CareEvaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People with T2 Diabetes2023
2023-08-30Intercept Pharma Europe Ltd.$17,290Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-08-30Medline Industries LP$2,600Research paymentCash or cash equivalent422299 Device, THIS IS MATERIAL NUMBER SQU422299BXOPTICELL VS. AQUACEL2023
2023-08-30PFIZER INC.$650Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2023
2023-08-24Intercept Pharma Europe Ltd.$11,764Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-08-24PFIZER INC.$717Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2023
2023-08-23Merck Sharp & Dohme LLC$13,586Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792023
2023-08-23Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2023
2023-08-22E.R. Squibb & Sons, L.L.C.$49,958Research paymentCash or cash equivalentMultidimensional IO markers of Response and Resistance To Checkpoint Inhibition in Cancer Patients2023
2023-08-22PFIZER INC.$942Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-08-18Acrotech Biopharma Inc.$11,660Research paymentCash or cash equivalentEVOMELA Drug, ONCOLOGYIIS-MEL-0032023
2023-08-18Novo Nordisk AS$2,565Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522023
2023-08-18Novo Nordisk AS$516Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522023
2023-08-17PFIZER INC.$3,770Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-08-16Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSublocade Drug, Opioid Use Disorder2023
2023-08-16Janssen Research & Development, LLC$3,900Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-08-16Janssen Research & Development, LLC$492Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-08-14PFIZER INC.$137,066Research paymentCash or cash equivalentULTRASTRUCTURAL ANALYSIS OF PODOCYTE FOOT PROCESS WIDTH AND OTHER HISTOLOGICAL ANALYSES OF KIDNEY DISEASE SAMPLES AND BI2023
2023-08-11Janssen Research & Development, LLC$18,648Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2023
2023-08-11Janssen Research & Development, LLC$11,250Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2023
2023-08-11CSL Behring$10,400Research paymentCash or cash equivalentKcentra Biological, Trauma (Emergency, Injury, Surgery)A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1112023
2023-08-11CSL Behring$4,225Research paymentCash or cash equivalentKcentra Biological, Trauma (Emergency, Injury, Surgery)A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1112023
2023-08-11CSL Behring$3,250Research paymentCash or cash equivalentKcentra Biological, Trauma (Emergency, Injury, Surgery)A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1112023
2023-08-11CSL Behring$1,500Research paymentCash or cash equivalentKcentra Biological, Trauma (Emergency, Injury, Surgery)A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1112023
2023-08-10Janssen Research & Development, LLC$238Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2023
2023-08-09PFIZER INC.$2,892Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-08-08Immedica Pharma US, Inc.$1,905Research paymentIn-kind items and servicesA Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St2023
2023-08-03Mannkind Corporation$20,345Research paymentCash or cash equivalentAFREZZA Drug, DIABETES MEDICINEINHALE-32023
2023-08-03Intercept Pharma Europe Ltd.$2,926Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2023
2023-08-03ABBVIE INC.$2,600Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYA Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexa2023
2023-08-03Medline Industries LP$1,911Research paymentCash or cash equivalent422299 Device, THIS IS MATERIAL NUMBER SQU422299BXOPTICELL VS. AQUACEL2023
2023-08-02Agios Pharmaceuticals, Inc.$4,399Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$4,066Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$3,987Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$2,972Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$2,632Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$2,329Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$2,329Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$2,286Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$2,244Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$1,689Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02Agios Pharmaceuticals, Inc.$1,689Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Voluntee2023
2023-08-02PFIZER INC.$1,225Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2023
2023-07-31Novo Nordisk AS$3,598Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522023
2023-07-28Janssen Research & Development, LLC$3,191Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$3,184Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$3,158Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$3,070Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$1,933Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$1,933Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$1,933Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$1,060Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$1,060Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$1,060Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$1,060Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$934Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$827Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$827Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$234Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$234Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$234Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$234Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023
2023-07-28Janssen Research & Development, LLC$234Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092023

The latest 200 records of 510.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Suffolk CountyBoston city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.

MeasurePlace (city or town)
Boston, MA
County
Suffolk County, MA
State
Massachusetts
Population B01003666,442785,1217,044,056
Population, 2020 census P1675,647797,9367,029,917
Median age B0100233.333.940.0
Under 18 B0100115.1%16.0%19.4%
65 and over B0100113.0%13.3%17.9%
Households B11001283,374327,1672,785,042
Foreign born B0500227.8%29.8%18.0%
Median household income B19013$97,344$95,631$103,960
Median family income B19113$116,436$112,072$131,675
Per capita income B19301$61,698$58,636$57,897
Poverty rate B1700116.6%16.2%10.0%
Unemployment rate B230256.1%6.3%5.2%
Civilian labor force B23025402,354468,6363,911,446
Mean commute (minutes) B0801330.330.929.1
Bachelor's degree or higher B1500354.9%50.6%47.3%
Housing units B25001310,625357,2903,030,406
Owner-occupied B2500335.7%36.5%62.5%
Renters B2500364.3%63.5%37.5%
Median home value B25077$731,700$705,800$562,100
Median gross rent B25064$2,147$2,129$1,762
White, not Hispanic B0300244.1%43.6%66.6%
Black B0300219.3%17.1%6.4%
Hispanic or Latino B0300219.3%23.2%13.3%
Asian B0300210.3%9.2%7.3%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.